A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, Gennaro, Boess, Frank G., Taylor, Kirsten I., Ricci, Benedicte, Mollenhauer, Brit, Poewe, Werner, Boulay, Anne, Anzures-Cabrera, Judith, Vogt, Annamarie, Marchesi, Maddalena, Post, Anke, Nikolcheva, Tania, Kinney, Gene G., Zago, Wagner M., Ness, Daniel K., Svoboda, Hanno, Britschgi, Markus, Ostrowitzki, Susanne, Simuni, Tanya, Marek, Kenneth, Koller, Martin, Sevigny, Jeff, Doody, Rachelle, Fontoura, Paulo, Umbricht, Daniel, Bonni, Azad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518716/
https://www.ncbi.nlm.nih.gov/pubmed/34659081
http://dx.doi.org/10.3389/fneur.2021.705407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518716/
https://www.ncbi.nlm.nih.gov/pubmed/34659081
http://dx.doi.org/10.3389/fneur.2021.705407

Ejemplares similares